CorMedix (CRMD) shares were up over 20% in recent trading on Tuesday after its Q1 net income and revenue surpassed analysts' consensus.
The company reported Q1 results swung to net income Tuesday of $0.30 per diluted share, from a loss of $0.25 a year earlier.
Analysts polled by FactSet expected EPS of $0.26.
Revenue for the quarter ended March 31 was $39.1 million.
Analysts surveyed by FactSet expected $36.9 million.
CorMedix expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million.
As of March 31, the company said it had $77.5 million in cash and/or cash equivalents on hand, and expected it could fund operations for at least 12 months from the issuance of its quarterly report on From 10-Q.
Price: 10.92, Change: +1.89, Percent Change: +20.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.